U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Hyperprogression

MedGen UID:
1714714
•Concept ID:
C5236985
•
Pathologic Function

Definition

Paradoxical acceleration of tumor progression following the initiation of therapy. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVHyperprogression

Professional guidelines

PubMed

Management of cutaneous melanoma: radiologists challenging and risk assessment.
Granata V, Simonetti I, Fusco R, Setola SV, Izzo F, Scarpato L, Vanella V, Festino L, Simeone E, Ascierto PA, Petrillo A
Radiol Med 2022 Aug;127(8):899-911. Epub 2022 Jul 14 doi: 10.1007/s11547-022-01522-4. PMID: 35834109
Non-invasive decision support for NSCLC treatment using PET/CT radiomics.
Mu W, Jiang L, Zhang J, Shi Y, Gray JE, Tunali I, Gao C, Sun Y, Tian J, Zhao X, Sun X, Gillies RJ, Schabath MB
Nat Commun 2020 Oct 16;11(1):5228. doi: 10.1038/s41467-020-19116-x. PMID: 33067442Free PMC Article
Treatment after progression in the era of immunotherapy.
Billan S, Kaidar-Person O, Gil Z
Lancet Oncol 2020 Oct;21(10):e463-e476. doi: 10.1016/S1470-2045(20)30328-4. PMID: 33002442

Recent clinical studies

Etiology

First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial.
Özgüroğlu M, Kilickap S, Sezer A, Gümüş M, Bondarenko I, Gogishvili M, Nechaeva M, Schenker M, Cicin I, Ho GF, Kulyaba Y, Zyuhal K, Scheusan RI, Garassino MC, He X, Kaul M, Okoye E, Li Y, Li S, Pouliot JF, Seebach F, Lowy I, Gullo G, Rietschel P
Lancet Oncol 2023 Sep;24(9):989-1001. Epub 2023 Aug 14 doi: 10.1016/S1470-2045(23)00329-7. PMID: 37591293
Emerging and Evolving Concepts in Cancer Immunotherapy Imaging.
Dercle L, Sun S, Seban RD, Mekki A, Sun R, Tselikas L, Hans S, Bernard-Tessier A, Mihoubi Bouvier F, Aide N, Vercellino L, Rivas A, Girard A, Mokrane FZ, Manson G, Houot R, Lopci E, Yeh R, Ammari S, Schwartz LH
Radiology 2023 Jan;306(1):32-46. Epub 2022 Dec 6 doi: 10.1148/radiol.210518. PMID: 36472538
Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer.
Hu J, Yu A, Othmane B, Qiu D, Li H, Li C, Liu P, Ren W, Chen M, Gong G, Guo X, Zhang H, Chen J, Zu X
Theranostics 2021;11(7):3089-3108. Epub 2021 Jan 1 doi: 10.7150/thno.53649. PMID: 33537076Free PMC Article
Pseudoprogression and Hyperprogression as New Forms of Response to Immunotherapy.
Frelaut M, du Rusquec P, de Moura A, Le Tourneau C, Borcoman E
BioDrugs 2020 Aug;34(4):463-476. doi: 10.1007/s40259-020-00425-y. PMID: 32394415
Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate.
Kato S, Goodman A, Walavalkar V, Barkauskas DA, Sharabi A, Kurzrock R
Clin Cancer Res 2017 Aug 1;23(15):4242-4250. Epub 2017 Mar 28 doi: 10.1158/1078-0432.CCR-16-3133. PMID: 28351930Free PMC Article

Diagnosis

Electrolyte and Acid-Base Disorders Associated with Cancer Immunotherapy.
Uppal NN, Workeneh BT, Rondon-Berrios H, Jhaveri KD
Clin J Am Soc Nephrol 2022 Jun;17(6):922-933. Epub 2022 Jan 21 doi: 10.2215/CJN.14671121. PMID: 35063968Free PMC Article
Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer.
Hu J, Yu A, Othmane B, Qiu D, Li H, Li C, Liu P, Ren W, Chen M, Gong G, Guo X, Zhang H, Chen J, Zu X
Theranostics 2021;11(7):3089-3108. Epub 2021 Jan 1 doi: 10.7150/thno.53649. PMID: 33537076Free PMC Article
Non-invasive decision support for NSCLC treatment using PET/CT radiomics.
Mu W, Jiang L, Zhang J, Shi Y, Gray JE, Tunali I, Gao C, Sun Y, Tian J, Zhao X, Sun X, Gillies RJ, Schabath MB
Nat Commun 2020 Oct 16;11(1):5228. doi: 10.1038/s41467-020-19116-x. PMID: 33067442Free PMC Article
Pseudoprogression and hyperprogression in lung cancer: a comprehensive review of literature.
Zhou L, Zhang M, Li R, Xue J, Lu Y
J Cancer Res Clin Oncol 2020 Dec;146(12):3269-3279. Epub 2020 Aug 28 doi: 10.1007/s00432-020-03360-1. PMID: 32857178
Hyperprogression under Immunotherapy.
Frelaut M, Le Tourneau C, Borcoman E
Int J Mol Sci 2019 May 30;20(11) doi: 10.3390/ijms20112674. PMID: 31151303Free PMC Article

Therapy

Emerging and Evolving Concepts in Cancer Immunotherapy Imaging.
Dercle L, Sun S, Seban RD, Mekki A, Sun R, Tselikas L, Hans S, Bernard-Tessier A, Mihoubi Bouvier F, Aide N, Vercellino L, Rivas A, Girard A, Mokrane FZ, Manson G, Houot R, Lopci E, Yeh R, Ammari S, Schwartz LH
Radiology 2023 Jan;306(1):32-46. Epub 2022 Dec 6 doi: 10.1148/radiol.210518. PMID: 36472538
Electrolyte and Acid-Base Disorders Associated with Cancer Immunotherapy.
Uppal NN, Workeneh BT, Rondon-Berrios H, Jhaveri KD
Clin J Am Soc Nephrol 2022 Jun;17(6):922-933. Epub 2022 Jan 21 doi: 10.2215/CJN.14671121. PMID: 35063968Free PMC Article
Non-invasive decision support for NSCLC treatment using PET/CT radiomics.
Mu W, Jiang L, Zhang J, Shi Y, Gray JE, Tunali I, Gao C, Sun Y, Tian J, Zhao X, Sun X, Gillies RJ, Schabath MB
Nat Commun 2020 Oct 16;11(1):5228. doi: 10.1038/s41467-020-19116-x. PMID: 33067442Free PMC Article
Clinical Challenges of Immune Checkpoint Inhibitors.
de Miguel M, Calvo E
Cancer Cell 2020 Sep 14;38(3):326-333. Epub 2020 Aug 3 doi: 10.1016/j.ccell.2020.07.004. PMID: 32750319
PD-1 expression and clinical PD-1 blockade in B-cell lymphomas.
Xu-Monette ZY, Zhou J, Young KH
Blood 2018 Jan 4;131(1):68-83. Epub 2017 Nov 8 doi: 10.1182/blood-2017-07-740993. PMID: 29118007Free PMC Article

Prognosis

First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial.
Özgüroğlu M, Kilickap S, Sezer A, Gümüş M, Bondarenko I, Gogishvili M, Nechaeva M, Schenker M, Cicin I, Ho GF, Kulyaba Y, Zyuhal K, Scheusan RI, Garassino MC, He X, Kaul M, Okoye E, Li Y, Li S, Pouliot JF, Seebach F, Lowy I, Gullo G, Rietschel P
Lancet Oncol 2023 Sep;24(9):989-1001. Epub 2023 Aug 14 doi: 10.1016/S1470-2045(23)00329-7. PMID: 37591293
Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer.
Hu J, Yu A, Othmane B, Qiu D, Li H, Li C, Liu P, Ren W, Chen M, Gong G, Guo X, Zhang H, Chen J, Zu X
Theranostics 2021;11(7):3089-3108. Epub 2021 Jan 1 doi: 10.7150/thno.53649. PMID: 33537076Free PMC Article
Non-invasive decision support for NSCLC treatment using PET/CT radiomics.
Mu W, Jiang L, Zhang J, Shi Y, Gray JE, Tunali I, Gao C, Sun Y, Tian J, Zhao X, Sun X, Gillies RJ, Schabath MB
Nat Commun 2020 Oct 16;11(1):5228. doi: 10.1038/s41467-020-19116-x. PMID: 33067442Free PMC Article
Hyperprogression under Immunotherapy.
Frelaut M, Le Tourneau C, Borcoman E
Int J Mol Sci 2019 May 30;20(11) doi: 10.3390/ijms20112674. PMID: 31151303Free PMC Article
PD-1 expression and clinical PD-1 blockade in B-cell lymphomas.
Xu-Monette ZY, Zhou J, Young KH
Blood 2018 Jan 4;131(1):68-83. Epub 2017 Nov 8 doi: 10.1182/blood-2017-07-740993. PMID: 29118007Free PMC Article

Clinical prediction guides

Electrolyte and Acid-Base Disorders Associated with Cancer Immunotherapy.
Uppal NN, Workeneh BT, Rondon-Berrios H, Jhaveri KD
Clin J Am Soc Nephrol 2022 Jun;17(6):922-933. Epub 2022 Jan 21 doi: 10.2215/CJN.14671121. PMID: 35063968Free PMC Article
Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer.
Hu J, Yu A, Othmane B, Qiu D, Li H, Li C, Liu P, Ren W, Chen M, Gong G, Guo X, Zhang H, Chen J, Zu X
Theranostics 2021;11(7):3089-3108. Epub 2021 Jan 1 doi: 10.7150/thno.53649. PMID: 33537076Free PMC Article
Non-invasive decision support for NSCLC treatment using PET/CT radiomics.
Mu W, Jiang L, Zhang J, Shi Y, Gray JE, Tunali I, Gao C, Sun Y, Tian J, Zhao X, Sun X, Gillies RJ, Schabath MB
Nat Commun 2020 Oct 16;11(1):5228. doi: 10.1038/s41467-020-19116-x. PMID: 33067442Free PMC Article
Hyperprogression under Immunotherapy.
Frelaut M, Le Tourneau C, Borcoman E
Int J Mol Sci 2019 May 30;20(11) doi: 10.3390/ijms20112674. PMID: 31151303Free PMC Article
PD-1 expression and clinical PD-1 blockade in B-cell lymphomas.
Xu-Monette ZY, Zhou J, Young KH
Blood 2018 Jan 4;131(1):68-83. Epub 2017 Nov 8 doi: 10.1182/blood-2017-07-740993. PMID: 29118007Free PMC Article

Recent systematic reviews

Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer.
Soria F, Beleni AI, D'Andrea D, Resch I, Gust KM, Gontero P, Shariat SF
World J Urol 2018 Nov;36(11):1703-1709. Epub 2018 Mar 16 doi: 10.1007/s00345-018-2264-0. PMID: 29549485Free PMC Article

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...